TY  - JOUR
A1  - Steinhardt, Maximilian Johannes
A1  - Zhou, Xiang
A1  - Krummenast, Franziska
A1  - Meckel, Katharina
A1  - Nickel, Katharina
A1  - Böckle, David
A1  - Messerschmidt, Janin
A1  - Knorz, Sebastian
A1  - Dierks, Alexander
A1  - Heidemeier, Anke
A1  - Lapa, Constantin
A1  - Einsele, Hermann
A1  - Rasche, Leo
A1  - Kortüm, Klaus Martin
T1  - Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
JF  - International Journal of Immunopathology and Pharmacology
N2  - We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab (“Pom-PAD-Dara”), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.
KW  - CD38
KW  - MOR202
KW  - daratumumab
KW  - multiple myeloma
KW  - refractory
KW  - relapse
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-236235
VL  - 34
ER  - 
TY  - JOUR
A1  - Zhou, Xiang
A1  - Ruckdeschel, Anna
A1  - Peter, Jessica
A1  - Böckle, David
A1  - Hornburger, Hannah
A1  - Danhof, Sophia
A1  - Steinhardt, Maximilian Johannes
A1  - Heimeshoff, Larissa
A1  - Einsele, Hermann
A1  - Kortüm, Klaus Martin
A1  - Rasche, Leo
T1  - Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
JF  - Hematological Oncology
N2  - The multi-agent therapy “VDT-PACE” represents an established regimen in relapsed/refractory multiple myeloma (RRMM). Here, we report on our experience with a “modified VDT-PACE” incorporating new generation anti-MM agents daratumumab and carfilzomib (“Dara-KDT-P(A)CE”). We retrospectively analyzed 38 patients with RRMM treated with “Dara-KDT-P(A)CE”. The median age was 62 (range 45–82) years, and the patients were heavily pretreated with a median of 5 (range 2–12) prior lines of therapy. Twenty-one (55%) patients suffered from penta-refractory MM. High-risk cytogenetics was present in 31 (81%) patients. The patients received a median of 2 (range 1–10) cycles of this therapy, and the overall response rate (ORR) was 70%. Patients with penta-refractory MM and high-risk cytogenetics showed similar ORR of 65% and 79%, respectively. The median progression-free survival (PFS) and overall survival were 4.1 (95% CI 2.7–5.4) and 8.4 (95% CI 6.7–10.0) months, respectively. Patients with lactate dehydrogenase >250 IU/L showed significantly shorter PFS in comparison with others patients (p = 0.006). We used this regimen as bridging therapy prior to chimeric antigen receptor T-cell infusion in four patients. In conclusion, “Dara-KDT-P(A)CE” is an effective salvage therapy for patients with heavily pretreated, multi-refractory, high-risk RRMM lacking alternative options.
KW  - Dara-KDT-P(A)CE
KW  - multiple myeloma
KW  - refractory
KW  - salvage
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-257495
VL  - 40
IS  - 2
ER  -